<unk> , sold under the brand name Zerbaxa, is a combination antibiotic medication used for the treatment of complicated urinary tract infections and complicated intra-abdominal infections in adults.<unk>  is a cephalosporin antibiotic, developed for the treatment of infections with gram-negative bacteria that are resistant to conventional antibiotics. It was studied for urinary tract infections, intra-abdominal infections and ventilator-associated bacterial pneumonia. The most common side effects include nausea (feeling sick), headache, constipation, diarrhea and fever.<unk>  is a type of antibiotic called a cephalosporin, which belongs to the wider group of antibiotics called beta-lactams. It works by interfering with the production of molecules that bacteria need to build their protective cell walls. This causes weakness in the bacterial cell walls which then become prone to collapse, ultimately leading to the death of the bacteria<unk>  blocks the action of bacterial enzymes called beta-lactamases. These enzymes enable bacteria to break down beta-lactam antibiotics like<unk> , making the bacteria resistant to the antibiotic's action. By blocking the action of these enzymes,<unk>  allows<unk>  to act against bacteria that would otherwise be resistant to<unk> .<unk>  is combined with the β-lactamase inhibitor<unk> , which protects<unk>  from degradation. It was approved for medical use in the United States in December 2014, and in the European Union in September 2015.
Ceftolozane/tazobactam
Imipenem/cilastatin
Imipenem/cilastatin/relebactam
Ceftazidime/avibactam
Piperacillin/tazobactam
Ampicillin/sulbactam
Meropenem/vaborbactam
Tobramycin/dexamethasone